



Australia's
Global
University

Australia's universal access strategy: Lump-sum remuneration and reaching marginalized populations

Scientia Professor Gregory Dore



Kirby Institute

Disclosures

- Research grants, travel support, and honoraria: AbbVie, Gilead, Merck
-

Australian Government DAA program

Features


- **Mar 2016:** unrestricted DAA access – no liver disease stage, drug and alcohol use restrictions
- All patients with chronic HCV aged 18 years+
- Involvement of non-specialists in DAA prescribing
- Minimal administration for clinicians; minimal co-payment for patients (\$AUD 7–37/month)
- DAA dispensing in hospital and community pharmacies
- No cap on treatment numbers – including retreatment for failure or reinfection
- Cap on annual expenditure – exact details confidential, but probably \$AUD 200-250 M
- 5 year contract period: Mar 2016–Feb 2021

WIN, WIN, WIN


Australian Government DAA program

DAA	US licence	US list price (\$US, 12 weeks)	AUS registered (TGA approved)	PBAC recommended	AUS funded (PBS listed)	US licence to AUS funded
Sofosbuvir + ribavirin (+PEG-IFN)	DEC 2013	\$84,000	JUN 2014	MAR 2015	MAR 2016	27 months
Sofosbuvir/ledipasvir	OCT 2014	\$84,000	MAY 2015	MAR 2015	MAR 2016	17 months
Paritaprevir/r/ombitasvir + dasabuvir	DEC 2014	\$83,000	JUL 2015	JUL 2015	MAY 2016	20 months
Sofosbuvir + daclatasvir	JUL 2015	\$146,000	JUN 2015	MAR 2015	MAR 2016	8 months
Elbasvir/grazoprevir	JAN 2016	\$54,600	AUG 2016	JUL 2016	JAN 2017	12 months
Sofosbuvir/velpatasvir	JUN 2016	\$75,000	DEC 2016	NOV 2016	AUG 2017	14 months
Glecaprevir/pibrentasvir	AUG 2017	\$39,600 (\$26,400; 8 wks)	JAN 2018	NOV 2017	AUG 2018	12 months
Sofosbuvir/velpatasvir/voxilaprevir	JUL 2017	\$74,760	MAR 2018	MAR 2018	MAR 2019	20 months


HCV treatment uptake in Australia: 1997–2018



The emergence of pan-genotypic DAA therapy




Increasing proportion of non-specialist treatment



High DAA efficacy across all sub-populations

REACH-C study: Per protocol analysis* (n=4,513)




Initiations from Mar 2016 – Dec 2017

IDU: injecting drug use; OST: opioid substitution therapy

*(n=903 with unknown SVR; 17%)

High DAA efficacy across all service models

REACH-C study: Per protocol analysis* (n=4,513)




Initiations from Mar 2016 – Dec 2017

*(n=903 with unknown SVR; 17%)

DAA uptake high in current PWID

Annual Needle Syringe Program Survey (n = 2,000-2,500)

Ever HCV Treatment
among Chronic HCV (%)




HCV elimination in HIV population



HCV RNA prevalence among HIV/HCV cohort (antibody +ve)


% HCV RNA+



HCV elimination (near) in QLD prison: Lotus Glen


HCV burden within prison (800-850 inmates)

% HCV RNA+




ESLD and liver-related deaths: NSW data linkage


Decompensated cirrhosis




Hepatocellular carcinoma



Liver-related deaths



Australia's DAA program: the "Netflix" model



The estimated total no. of patients in February 2018 was 47,122. Estimate+projection includes 104,223 people and yields a **price per patient of AU\$9,595 (U.S.\$7,352)**. Sensitivity analysis includes 71,372 people and yields a price per patient of AU\$14,011 (U.S.\$10,736). Government estimate includes 61,500 people and yields a price per patient of AU\$16,260 (U.S.\$12,460).

Acknowledgements



UNSW Sydney

A/Prof. Jason Grebely
A/Prof. Gail Matthews
Prof. Andrew Lloyd
Prof. Carla Treloar
Prof. Louisa Degenhardt
Prof. Michael Farrell
Dr. Behzad Hajarizadeh
Dr. Maryam Alavi
Dr. Tanya Applegate
Dr. Marianne Martinello
Ms. Pip Marks
Dr. Richard Gray
Dr. Amy Known
Prof. Lisa Maher
Dr. Jenny Iversen



Collaborators

Prof. Margaret Hellard (Australia)
Dr. Joe Doyle (Australia)
Prof. Alex Thompson (Australia)
Prof. Jacob George (Australia)
Prof. Ed Gane (New Zealand)
A/Prof. Natasha Martin (USA)
Prof. Peter Vickerman (UK)
Prof. Matt Hickman (UK)
Dr. Homie Razavi (USA)
Dr. Philip Bruggmann (Switzerland)
Prof. Olav Dalgard (Norway)
Prof. Julie Bruneau (Canada)
Dr. Jordan Feld (Canada)



@GregDore2 for “All things Hep C”